AI Cuts Birth Defect Test Wait from 30 Days to One Week

Families waiting weeks for critical genetic test results during pregnancy might soon get answers in days instead, thanks to a breakthrough AI system that just earned unprecedented regulatory approval in China.

Hangzhou Diagens Biotechnology announced that its AI AutoVision software received Class III certification from China's National Medical Products Administration on May 22. This marks the first time any AI system for analyzing chromosome images has achieved the country's highest level of medical device approval.

The technology tackles a problem that has frustrated doctors and anxious families for decades. Traditionally, trained specialists must spend about 34 minutes manually examining, counting, and arranging all 46 chromosomes under a microscope for each patient. The painstaking work creates bottlenecks, with families typically waiting 30 days for results that determine whether their baby has genetic conditions like Down syndrome.

Training someone to do this work takes three to five years, and there simply aren't enough specialists to meet demand. AI AutoVision changes that equation entirely by automating the analysis while doctors review the results.

The system proved itself in a rigorous trial involving 1,734 cases across multiple medical centers. It caught 100% of numerical chromosome abnormalities with perfect accuracy and detected 94% of structural problems. Most importantly, it cut average analysis time from 34 minutes to just 11 minutes, shrinking the wait for results from roughly a month to four to seven days.

The Ripple Effect

This approval matters beyond one product. The AI system runs on a massive foundation model containing 104 billion parameters that can analyze 19 different types of medical images. Think of it like a master key that unlocked one door but can open many others.

Diagens has already partnered with 65 leading hospitals to develop 92 additional imaging tools covering 32 organs and 64 disease areas. The Class III approval proves their underlying technology can pass the strictest regulatory scrutiny, paving the way for faster development of similar tools.

For hospitals, this means access to specialist-level analysis without the years-long wait to train new staff. For families facing prenatal diagnoses or fertility treatments, it means less time in limbo and faster paths to treatment decisions.

The regulatory barrier itself creates a protective advantage. Earning Class III certification typically requires two to three years of clinical trials and rigorous safety testing, giving Diagens a significant head start in a market desperate for solutions.

Thousands of families will soon spend less time worrying and more time planning their next steps with accurate information in hand.